Stock AB AB SCIENCE
Add to a list
To use this feature you must be a member
Log inSign up

AB Science Stock

Equities

AB

FR0010557264

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 11:35:01 2024-05-10 am EDT 		5-day change 1st Jan Change
1.99 EUR +0.40% Intraday chart for AB Science +1.02% -44.02%
May. 03 AB Science: upbeat after legal success CF
May. 03 French Appeals Court Acquits AB Science CEO of Insider Trading Charges MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2023 * 930K 1M Sales 2024 * 990K 1.07M Capitalization 102M 109M
Net income 2023 * -19M -20.46M Net income 2024 * -18M -19.38M EV / Sales 2023 * 109 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 103 x
P/E ratio 2023 *
-5.24 x
P/E ratio 2024 *
-5.53 x
Employees 89
Yield 2023 *
-
Yield 2024 *
-
Free-Float 66.05%
More Fundamentals * Assessed data

Chart AB Science

Dynamic Chart

Latest news about AB Science

AB Science: upbeat after legal success CF
French Appeals Court Acquits AB Science CEO of Insider Trading Charges MT
AB Science S.A. Announces Slight Delay in Publication of Annual Financial Report 2023 CI
AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada MT
AB Science: reconsideration possible for masitinib in ALS CF
AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS CI
AB Science: encouraging results for masitinib CF
Transcript : AB Science S.A. - Special Call
AB Science: share price falls, negative opinion in Canada CF
AB Science: share price falls, CHMP verdict postponed CF
AB Science: medical use patent for masitinib CF
AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis CI
Transcript : AB Science S.A. - Special Call
AB Science: project selected for public funding CF
AB Science S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news

Latest transcript on AB Science

Logo AB Science
AB Science S.A. - Special Call
More transcripts

Analyst Recommendations on AB Science

AB Science : Masitinib Treatment Against Pancreatic Cancer Boosts Survival Rates MT
SCIENCE : AB Science: Chardan Capital Markets initiates coverage with a BUY recommendation on AB Science and a target price of €30 GL
More recommendations

Press releases AB Science

AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient GL
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science GL
AB Science announces a slight delay in the publication of its 2023 annual financial report GL
AB Science announces a slight delay in the publication of its 2023 annual financial report AQ
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS GL
More press releases

News in other languages on AB Science

AB Science
AB Science : bien orienté après un succès en justice
AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB Science
AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023
DBT : Air France KLM, Capgemini, Imerys, Vetoquinol... les valeurs à suivre demain à la Bourse de Paris
More news

Quotes and Performance

1 day+0.40%
1 week+1.02%
Current month+3.75%
1 month-9.34%
3 months-40.60%
6 months-19.11%
Current year-44.02%
More quotes

Highs and lows

1 week
1.95
Extreme 1.95
2.07
1 month
1.86
Extreme 1.862
2.28
Current year
1.55
Extreme 1.55
4.47
1 year
1.55
Extreme 1.55
5.31
3 years
1.55
Extreme 1.55
16.68
5 years
1.55
Extreme 1.55
21.75
10 years
1.55
Extreme 1.55
21.75
More quotes

Managers and Directors - AB Science

Managers TitleAgeSince
Alain Moussy CEO
 Chief Executive Officer - 01-07-10
Laurent Guy DFI
 Director of Finance/CFO - 01-12-31
Christian Fassotte CTO
 Chief Tech/Sci/R&D Officer - 18-03-31
Members of the board TitleAgeSince
Alain Moussy CEO
 Chief Executive Officer - 01-07-10
Patrick Moussy BRD
 Director/Board Member - 01-07-10
Cécile de Guillebon BRD
 Director/Board Member 62 21-06-26
More insiders

ETFs positioned on AB Science

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Developed Ex-US Plus Downside Convexity ETF - USD
0.00% 10 M€ -3.35% -
More ETFs positioned on AB Science

Quotes

Date Price Change Volume
24-05-10 1.99 +0.40% 76,250
24-05-09 1.982 -2.36% 71,722
24-05-08 2.03 +1.50% 111,457
24-05-07 2 +0.20% 41,262
24-05-06 1.996 +1.32% 65,616

Real-time Euronext Paris, May 10, 2024 at 11:35 am EDT

More quotes

Company Profile

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-09-29 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.99 EUR
Average target price
6.895 EUR
Spread / Average Target
+246.48%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
AB SCIENCE Stock AB Science
-44.02% 109M
MERCK KGAA Stock Merck KGaA
+7.91% 72.81B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.64% 9.13B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-10.56% 5.13B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+58.79% 4.99B
YUHAN CORPORATION Stock Yuhan Corporation
+4.07% 3.9B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-16.90% 2.48B
INDIVIOR PLC Stock Indivior PLC
+20.84% 2.42B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-26.13% 2.32B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+19.31% 2.17B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AB Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW